Form 4: Cytokinetics CEO Gifts Shares to Family Trusts

Cytokinetics President and CEO Robert I Blum gifted 2,000 shares of common stock to two irrevocable family trusts.

Summary

• Robert I Blum, President & CEO and a Director of Cytokinetics Inc. (CYTK), reported a disposition of common stock.
• On November 5, 2025, Mr. Blum gifted 2,000 shares of Cytokinetics common stock.
• The transaction was executed at a price of $0 per share, consistent with a gift.
• The shares were transferred to The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust.
• Following this transaction, Mr. Blum directly beneficially owns 356,108 shares of common stock.
• Additionally, 2,083 shares are indirectly owned by Trust 1 and 2,083 shares by Trust 2.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a personal gift transaction by an insider, not a sale for value or a purchase, and does not directly reflect on the company's operational performance or financial health.

Positives

• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent disposition strategy.

Negatives

• The transaction represents a reduction in the direct beneficial ownership of common stock by a key executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This is an insider transaction filing, which typically reflects personal financial planning by an executive rather than a direct reflection of broader industry trends or competitive positioning. It does not provide insights into the biotechnology or pharmaceutical industry beyond the individual's holdings in Cytokinetics.

Related Party Transactions

• The disposition of shares was made to The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust, which are related parties to the reporting person, Robert I Blum.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in direct insider ownership, but the shares remain within family trusts, indicating continued indirect alignment of interests. The impact on the overall share structure is negligible.
• Employees, Customers, Suppliers, Creditors: No direct impact on these stakeholders is indicated by this insider transaction.

Key Dates

Keywords

Cytokinetics, CYTK, Robert I Blum, Insider Transaction, Form 4, Stock Gift, Beneficial Ownership, Trusts